Taurakalnio sveikatos namai - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 20,839 | 29,326 | 41,291 | 92,329 | 128,611 | 92,731 | 67,650 | 69,778 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -12,312 | -18,154 | -16,809 | -43,366 | 4,423 | -9,573 | -14,249 | -15,226 |
| Equity | -106,493 | -124,647 | -141,456 | -184,822 | -180,399 | -189,972 | -204,221 | -219,446 |
| Liabilities | 257,542 | 268,136 | 279,046 | 275,630 | 270,896 | 271,345 | 274,214 | 284,820 |
| Non-current assets | 106,757 | 99,164 | 91,571 | 83,978 | 76,385 | 68,878 | 62,212 | 55,545 |
| Current assets | 43,824 | 44,325 | 45,896 | 6,830 | 13,992 | 12,342 | 7,671 | 9,730 |
| Total assets | 150,581 | 143,489 | 137,467 | 90,808 | 90,377 | 81,220 | 69,883 | 65,275 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 8,817 | 6,442 | 7,405 |
| Social insurance contributions | - | - | - | - | - | 17,164 | 12,000 | 12,862 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +11.8% | +40.7% | +40.8% | +123.6% | +39.3% | -27.9% | -27.0% | +3.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -8.2% | -12.7% | -12.2% | -47.8% | 4.9% | -11.8% | -20.4% | -23.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -59.1% | -61.9% | -40.7% | -47.0% | 3.4% | -10.3% | -21.1% | -21.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,175 | 3,591 | 5,970 | 12,883 | 17,148 | 13,570 | 9,900 | 11,630 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Taurakalnio sveikatos namai - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-06-11 | 2025-06-12 | 0.11 |
| 2025-06-08 | 2025-06-09 | 0.11 |
| 2025-05-16 | 2025-06-04 | 0.11 |
| 2025-05-04 | 2025-05-13 | 0.11 |
| 2025-04-24 | 2025-04-29 | 0.11 |
| 2022-10-28 | 2022-11-13 | 0.11 |
| 2022-07-18 | 2022-07-19 | 74.33 |
| 2021-12-16 | 2022-01-13 | 2.29 |
| 2021-11-30 | 2021-12-14 | 2.29 |
| 2021-09-16 | 2021-09-16 | 1297.49 |
Taurakalnio sveikatos namai - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Taurakalnio sveikatos namai, UAB, is a Private Limited Liability Company operating in medical specialists activities (EVRK R.86.22.00). In 2025, the company generated revenue of €69.8K, up 3.1% year on year, after €67.7K in 2024 and €92.7K in 2023. Despite the recent stabilization in turnover, profitability remained negative: net loss was €15.2K in 2025, compared with a €14.2K loss in 2024 and a €9.6K loss in 2023. The 2025 profit margin stood at -21.8%, indicating continued pressure on operating results. The balance sheet remained strained, with total assets of €65.3K, equity of -€219.4K, and liabilities of €284.8K at the end of 2025. Asset levels declined from €81.2K in 2023 to €69.9K in 2024 and €65.3K in 2025, while liabilities continued to rise. Revenue per employee was €11.6K and profit per employee was -€2.5K in 2025. Asset turnover was 1.07x, showing moderate use of assets to generate sales, although the negative equity position means some balance-sheet ratios require cautious interpretation.